title: Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease.
abstract: Non-myeloablative allogeneic transplant (NMAT) has a curative potential for patients who are not myeloablative allogeneic transplant (MAT) candidates. We report a phase II trial of a NMAT regimen with cyclophosphamide and fludarabine in 40 patients; 21 of whom had a prior MAT. Day +100 and 1-year transplant-related mortality (TRM) post-NMAT were 13% and 34%, respectively. Day +100 and 1-year Overall/Progression-Free Survival (OS/PFS) were 80%/65% and 43%/25%, respectively. OS was higher in patients with KPS≥90 and lower in recipient/donor CMV+/- vs. other combinations. FluCy has low TRM and is curative in about 20% of high-risk patients.
authors.affiliation: Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States.
authors.forename: Pamela
authors.initials: P
authors.lastname: Paplham
authors.affiliation: Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States.
authors.forename: Theresa
authors.initials: T
authors.lastname: Hahn
authors.affiliation: Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States.
authors.forename: Karen
authors.initials: K
authors.lastname: Dubel
authors.affiliation: Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States.
authors.forename: Patricia
authors.initials: P
authors.lastname: Lipka
authors.affiliation: Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States.
authors.forename: Philip L
authors.initials: PL
authors.lastname: McCarthy
keywords: Allogeneic transplant; Cyclophosphamide; Fludarabine; Non-myeloablative